(Q52844170)

8 May 2018

title

Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. (English)

1 reference

8 May 2018

1 reference

2

1 reference

8 May 2018

author name string

Michael B Sprakes

1

1 reference

8 May 2018

Lisa Warren

3

1 reference

8 May 2018

Dan Greer

4

1 reference

8 May 2018

John Hamlin

5

1 reference

8 May 2018

publication date

31 August 2011

1 reference

8 May 2018

Journal of Crohn's and Colitis

published in

1 reference

8 May 2018

volume

6

1 reference

8 May 2018

issue

2

1 reference

8 May 2018

page(s)

143-153

1 reference

8 May 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Inflammatory bowel disease, irritable bowel syndrome, or what?: A challenge to the functional-organic dichotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Irritable bowel syndrome: a technical review for practice guideline development

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Durability of infliximab in Crohn's disease: a single-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.07.011

10.1016/J.CROHNS.2011.07.011

21 January 2018

Identifiers

DOI

1 reference

8 May 2018

release_6eminepqnrfgrdww6vbzuz2osy

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6eminepqnrfgrdww6vbzuz2osy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

8 May 2018